Speaker Profile

MS, MBA, President & CEO, CellMax Life

Atul cofounded CellMax Life in 2012, with the singular goal of developing globally affordable and quantitative bloodtests for Early Cancer Detection. He was motivated to start CellMax as two members of his family had been diagnosed with cancer one of them was diagnosed with breast cancer within two weeks of receiving a conclusively negative mammogram. Atul has experience as a serial entrepreneur, CEO and angel investor. Previously he was also resident at MohrDavidow Ventures and Artiman Ventures. He specializes in identifying unmet market needs and matching them with earlystage technologies to achieve dramatically better results than prevailing standards. He has done that successfully multiple times.


Clinical Dx Showcase:
CellMax Life

CellMax Life is developing blood tests for cancer screening. FirstSight is the first and only blood-test for preventive cancer screening that has also received Breakthrough designation from the FDA.

Blood-Test for Preventive Colon Cancer Screening
Blood Test for Colon Cancer Preventive Screening.

 Session Abstract – PMWC 2023 Silicon Valley

Showcase Track S2 - January 25 9.00 A.M.-1.15 P.M.,Showcase Track S2 - January 26 9.00 A.M.-4.45 P.M.,Showcase Track S2 - January 27 9.00 A.M.-2.15 P.M.

The PMWC 2023 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.

  • Clinical Dx/Oncology (including Liquid Biopsy)
  • Clinical Dx/Cardio Vascular
  • Clinical Dx/Nerodegenerative